A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms AMA
- 21 Feb 2021 Status changed from active, no longer recruiting to completed.
- 13 Feb 2020 Planned End Date changed from 1 Jul 2020 to 1 Feb 2021.
- 11 Oct 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.